BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Enasidenib

Differentiation Syndrome

  • Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution¬†[see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

FDA and Industry Communications

Index to FDA Safety Information

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Enasidenib Mesylate

Updated September 2017